Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Lunai Bioworks Inc.RENB · Entity 7981 | Chief Financial Officer | February 13, 2024 | February 16, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Lunai Bioworks Inc.
Report date February 13, 2024 · Filed February 16, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $6.15 · Expires 2029-06-06 | Direct | 0 |
Reported balance
After 2024-02-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-02-13 · Disposition to issuer · Disposed 60,000 · Balance 0 F2: The transactions reported herein reflect a stock option repricing (the "Option Repricing") effective on February 13, 2024 (the "Repricing Date"). Pursuant to the Option Repricing, which was approved by stockholders on January 25, 2024, the exercise price of all repriced options has been amended to $1.92 per share, the closing price of the Company's common stock, par value $0.0001 per share (the "Common Stock"), on the date of the closing of the Registrant's acquisition of GEDi Cube Intl Ltd. There were no other changes to the terms of the options. F1: The option vested in three equal installments on January 7, 2019, January 7, 2020 and January 7, 2021. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $1.92 · Expires 2029-06-06 | Direct | 60,000 |
Reported balance
After 2024-02-13 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-02-13 · Grant · Acquired 60,000 · Balance 60,000 F2: The transactions reported herein reflect a stock option repricing (the "Option Repricing") effective on February 13, 2024 (the "Repricing Date"). Pursuant to the Option Repricing, which was approved by stockholders on January 25, 2024, the exercise price of all repriced options has been amended to $1.92 per share, the closing price of the Company's common stock, par value $0.0001 per share (the "Common Stock"), on the date of the closing of the Registrant's acquisition of GEDi Cube Intl Ltd. There were no other changes to the terms of the options. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $8.58 · Expires 2031-10-26 | Direct | 0 |
Reported balance
After 2024-02-13 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-02-13 · Disposition to issuer · Disposed 60,000 · Balance 0 F2: The transactions reported herein reflect a stock option repricing (the "Option Repricing") effective on February 13, 2024 (the "Repricing Date"). Pursuant to the Option Repricing, which was approved by stockholders on January 25, 2024, the exercise price of all repriced options has been amended to $1.92 per share, the closing price of the Company's common stock, par value $0.0001 per share (the "Common Stock"), on the date of the closing of the Registrant's acquisition of GEDi Cube Intl Ltd. There were no other changes to the terms of the options. F3: The option vested in three equal installments on October 26, 2021, October 26, 2022 and October 26, 2023. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $1.92 · Expires 2031-10-26 | Direct | 60,000 |
Reported balance
After 2024-02-13 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-02-13 · Grant · Acquired 60,000 · Balance 60,000 F2: The transactions reported herein reflect a stock option repricing (the "Option Repricing") effective on February 13, 2024 (the "Repricing Date"). Pursuant to the Option Repricing, which was approved by stockholders on January 25, 2024, the exercise price of all repriced options has been amended to $1.92 per share, the closing price of the Company's common stock, par value $0.0001 per share (the "Common Stock"), on the date of the closing of the Registrant's acquisition of GEDi Cube Intl Ltd. There were no other changes to the terms of the options. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $2.38 · Expires 2032-07-22 | Direct | 0 |
Reported balance
After 2024-02-13 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-02-13 · Disposition to issuer · Disposed 75,000 · Balance 0 F2: The transactions reported herein reflect a stock option repricing (the "Option Repricing") effective on February 13, 2024 (the "Repricing Date"). Pursuant to the Option Repricing, which was approved by stockholders on January 25, 2024, the exercise price of all repriced options has been amended to $1.92 per share, the closing price of the Company's common stock, par value $0.0001 per share (the "Common Stock"), on the date of the closing of the Registrant's acquisition of GEDi Cube Intl Ltd. There were no other changes to the terms of the options. F4: The option vested on January 22, 2023. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $1.92 · Expires 2032-07-22 | Direct | 75,000 |
Reported balance
After 2024-02-13 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2024-02-13 · Grant · Acquired 75,000 · Balance 75,000 F2: The transactions reported herein reflect a stock option repricing (the "Option Repricing") effective on February 13, 2024 (the "Repricing Date"). Pursuant to the Option Repricing, which was approved by stockholders on January 25, 2024, the exercise price of all repriced options has been amended to $1.92 per share, the closing price of the Company's common stock, par value $0.0001 per share (the "Common Stock"), on the date of the closing of the Registrant's acquisition of GEDi Cube Intl Ltd. There were no other changes to the terms of the options. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $2.15 · Expires 2032-10-18 | Direct | 0 |
Reported balance
After 2024-02-13 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2024-02-13 · Disposition to issuer · Disposed 80,000 · Balance 0 F2: The transactions reported herein reflect a stock option repricing (the "Option Repricing") effective on February 13, 2024 (the "Repricing Date"). Pursuant to the Option Repricing, which was approved by stockholders on January 25, 2024, the exercise price of all repriced options has been amended to $1.92 per share, the closing price of the Company's common stock, par value $0.0001 per share (the "Common Stock"), on the date of the closing of the Registrant's acquisition of GEDi Cube Intl Ltd. There were no other changes to the terms of the options. F5: One third of the option vested on October 18, 2023, the remainder of the option vests equally on October 18, 2024 and October 18, 2025. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $1.92 · Expires 2032-10-18 | Direct | 80,000 |
Reported balance
After 2024-02-13 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2024-02-13 · Grant · Acquired 80,000 · Balance 80,000 F2: The transactions reported herein reflect a stock option repricing (the "Option Repricing") effective on February 13, 2024 (the "Repricing Date"). Pursuant to the Option Repricing, which was approved by stockholders on January 25, 2024, the exercise price of all repriced options has been amended to $1.92 per share, the closing price of the Company's common stock, par value $0.0001 per share (the "Common Stock"), on the date of the closing of the Registrant's acquisition of GEDi Cube Intl Ltd. There were no other changes to the terms of the options. F5: One third of the option vested on October 18, 2023, the remainder of the option vests equally on October 18, 2024 and October 18, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vested in three equal installments on January 7, 2019, January 7, 2020 and January 7, 2021.
F2: The transactions reported herein reflect a stock option repricing (the "Option Repricing") effective on February 13, 2024 (the "Repricing Date"). Pursuant to the Option Repricing, which was approved by stockholders on January 25, 2024, the exercise price of all repriced options has been amended to $1.92 per share, the closing price of the Company's common stock, par value $0.0001 per share (the "Common Stock"), on the date of the closing of the Registrant's acquisition of GEDi Cube Intl Ltd. There were no other changes to the terms of the options.
F3: The option vested in three equal installments on October 26, 2021, October 26, 2022 and October 26, 2023.
F4: The option vested on January 22, 2023.
F5: One third of the option vested on October 18, 2023, the remainder of the option vests equally on October 18, 2024 and October 18, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 13, 2024 Filed Feb 16, 2024 14:13 UTC | Lunai Bioworks Inc. RENB · Entity 7981 | GrantOption to Purchase Common Stock · Derivative | 80,000 | Not disclosed Strike: $1.92 | Not disclosed |
DisclosureSEC source: 0001731122-24-000264 · ownership.xml · derivative · entry 8 Puche Luisa · CIK 0001768468 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2032-10-18 F2 · price: The transactions reported herein reflect a stock option repricing (the "Option Repricing") effective on February 13, 2024 (the "Repricing Date"). Pursuant to the Option Repricing, which was approved by stockholders on January 25, 2024, the exercise price of all repriced options has been amended to $1.92 per share, the closing price of the Company's common stock, par value $0.0001 per share (the "Common Stock"), on the date of the closing of the Registrant's acquisition of GEDi Cube Intl Ltd. There were no other changes to the terms of the options. F5 · derivative.exercise_date: One third of the option vested on October 18, 2023, the remainder of the option vests equally on October 18, 2024 and October 18, 2025. Read SEC document |
| February 13, 2024 Filed Feb 16, 2024 14:13 UTC | Lunai Bioworks Inc. RENB · Entity 7981 | Disposition to issuerOption to Purchase Common Stock · Derivative | 80,000 | Not disclosed Strike: $2.15 | Not disclosed |
DisclosureSEC source: 0001731122-24-000264 · ownership.xml · derivative · entry 7 Puche Luisa · CIK 0001768468 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 80,000 shares Expires 2032-10-18 F2 · price: The transactions reported herein reflect a stock option repricing (the "Option Repricing") effective on February 13, 2024 (the "Repricing Date"). Pursuant to the Option Repricing, which was approved by stockholders on January 25, 2024, the exercise price of all repriced options has been amended to $1.92 per share, the closing price of the Company's common stock, par value $0.0001 per share (the "Common Stock"), on the date of the closing of the Registrant's acquisition of GEDi Cube Intl Ltd. There were no other changes to the terms of the options. F5 · derivative.exercise_date: One third of the option vested on October 18, 2023, the remainder of the option vests equally on October 18, 2024 and October 18, 2025. Read SEC document |
| February 13, 2024 Filed Feb 16, 2024 14:13 UTC | Lunai Bioworks Inc. RENB · Entity 7981 | GrantOption to Purchase Common Stock · Derivative | 75,000 | Not disclosed Strike: $1.92 | Not disclosed |
DisclosureSEC source: 0001731122-24-000264 · ownership.xml · derivative · entry 6 Puche Luisa · CIK 0001768468 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2032-07-22 F2 · price: The transactions reported herein reflect a stock option repricing (the "Option Repricing") effective on February 13, 2024 (the "Repricing Date"). Pursuant to the Option Repricing, which was approved by stockholders on January 25, 2024, the exercise price of all repriced options has been amended to $1.92 per share, the closing price of the Company's common stock, par value $0.0001 per share (the "Common Stock"), on the date of the closing of the Registrant's acquisition of GEDi Cube Intl Ltd. There were no other changes to the terms of the options. Read SEC document |
| February 13, 2024 Filed Feb 16, 2024 14:13 UTC | Lunai Bioworks Inc. RENB · Entity 7981 | Disposition to issuerOption to Purchase Common Stock · Derivative | 75,000 | Not disclosed Strike: $2.38 | Not disclosed |
DisclosureSEC source: 0001731122-24-000264 · ownership.xml · derivative · entry 5 Puche Luisa · CIK 0001768468 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 75,000 shares Expires 2032-07-22 F2 · price: The transactions reported herein reflect a stock option repricing (the "Option Repricing") effective on February 13, 2024 (the "Repricing Date"). Pursuant to the Option Repricing, which was approved by stockholders on January 25, 2024, the exercise price of all repriced options has been amended to $1.92 per share, the closing price of the Company's common stock, par value $0.0001 per share (the "Common Stock"), on the date of the closing of the Registrant's acquisition of GEDi Cube Intl Ltd. There were no other changes to the terms of the options. F4 · derivative.exercise_date: The option vested on January 22, 2023. Read SEC document |
| February 13, 2024 Filed Feb 16, 2024 14:13 UTC | Lunai Bioworks Inc. RENB · Entity 7981 | GrantOption to Purchase Common Stock · Derivative | 60,000 | Not disclosed Strike: $1.92 | Not disclosed |
DisclosureSEC source: 0001731122-24-000264 · ownership.xml · derivative · entry 4 Puche Luisa · CIK 0001768468 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2031-10-26 F2 · price: The transactions reported herein reflect a stock option repricing (the "Option Repricing") effective on February 13, 2024 (the "Repricing Date"). Pursuant to the Option Repricing, which was approved by stockholders on January 25, 2024, the exercise price of all repriced options has been amended to $1.92 per share, the closing price of the Company's common stock, par value $0.0001 per share (the "Common Stock"), on the date of the closing of the Registrant's acquisition of GEDi Cube Intl Ltd. There were no other changes to the terms of the options. Read SEC document |
| February 13, 2024 Filed Feb 16, 2024 14:13 UTC | Lunai Bioworks Inc. RENB · Entity 7981 | Disposition to issuerOption to Purchase Common Stock · Derivative | 60,000 | Not disclosed Strike: $8.58 | Not disclosed |
DisclosureSEC source: 0001731122-24-000264 · ownership.xml · derivative · entry 3 Puche Luisa · CIK 0001768468 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 60,000 shares Expires 2031-10-26 F2 · price: The transactions reported herein reflect a stock option repricing (the "Option Repricing") effective on February 13, 2024 (the "Repricing Date"). Pursuant to the Option Repricing, which was approved by stockholders on January 25, 2024, the exercise price of all repriced options has been amended to $1.92 per share, the closing price of the Company's common stock, par value $0.0001 per share (the "Common Stock"), on the date of the closing of the Registrant's acquisition of GEDi Cube Intl Ltd. There were no other changes to the terms of the options. F3 · derivative.exercise_date: The option vested in three equal installments on October 26, 2021, October 26, 2022 and October 26, 2023. Read SEC document |
| February 13, 2024 Filed Feb 16, 2024 14:13 UTC | Lunai Bioworks Inc. RENB · Entity 7981 | GrantOption to Purchase Common Stock · Derivative | 60,000 | Not disclosed Strike: $1.92 | Not disclosed |
DisclosureSEC source: 0001731122-24-000264 · ownership.xml · derivative · entry 2 Puche Luisa · CIK 0001768468 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2029-06-06 F2 · price: The transactions reported herein reflect a stock option repricing (the "Option Repricing") effective on February 13, 2024 (the "Repricing Date"). Pursuant to the Option Repricing, which was approved by stockholders on January 25, 2024, the exercise price of all repriced options has been amended to $1.92 per share, the closing price of the Company's common stock, par value $0.0001 per share (the "Common Stock"), on the date of the closing of the Registrant's acquisition of GEDi Cube Intl Ltd. There were no other changes to the terms of the options. Read SEC document |
| February 13, 2024 Filed Feb 16, 2024 14:13 UTC | Lunai Bioworks Inc. RENB · Entity 7981 | Disposition to issuerOption to Purchase Common Stock · Derivative | 60,000 | Not disclosed Strike: $6.15 | Not disclosed |
DisclosureSEC source: 0001731122-24-000264 · ownership.xml · derivative · entry 1 Puche Luisa · CIK 0001768468 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 60,000 shares Expires 2029-06-06 F2 · price: The transactions reported herein reflect a stock option repricing (the "Option Repricing") effective on February 13, 2024 (the "Repricing Date"). Pursuant to the Option Repricing, which was approved by stockholders on January 25, 2024, the exercise price of all repriced options has been amended to $1.92 per share, the closing price of the Company's common stock, par value $0.0001 per share (the "Common Stock"), on the date of the closing of the Registrant's acquisition of GEDi Cube Intl Ltd. There were no other changes to the terms of the options. F1 · derivative.exercise_date: The option vested in three equal installments on January 7, 2019, January 7, 2020 and January 7, 2021. Read SEC document |
| October 18, 2022 Filed Oct 27, 2022 20:51 UTC | Lunai Bioworks Inc. ENOB · Entity 7981 | GrantOption to purchase shares of common stock · Derivative | 80,000 | $0.00 Strike: $2.15 | $0.00 |
DisclosureSEC source: 0001731122-22-001810 · ownership.xml · derivative · entry 1 Puche Luisa · CIK 0001768468 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2032-10-18 F1 · derivative.exercise_date: This option vests ratably over three years commencing on October 18, 2023. Read SEC document |
| July 20, 2022 Filed Jul 26, 2022 23:02 UTC | Lunai Bioworks Inc. ENOB · Entity 7981 | GrantOption to purchase shares of common stock · Derivative | 75,000 | $0.00 Strike: $2.38 | $0.00 |
DisclosureSEC source: 0001731122-22-001245 · ownership.xml · derivative · entry 1 Puche Luisa · CIK 0001768468 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common stock · 75,000 shares Expires 2032-07-20 F1 · shares: The option was issued in connection with the Company's employee retention plan. Read SEC document |
| December 16, 2021 Filed Dec 21, 2021 00:01 UTC | Lunai Bioworks Inc. ENOB · Entity 7981 | GrantRestricted Stock Units · Derivative | 16,266 | $7.75 Strike: $7.75 | $126,061.50 |
DisclosureSEC source: 0001731122-21-002163 · ownership.xml · derivative · entry 1 Puche Luisa · CIK 0001768468 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,266 Underlying: Common Stock · 16,266 shares Expires 2031-12-16 F1 · shares: Each restricted stock unit represents a contingent right to receive one share of Enochian Biosciences Inc. common stock. F2 · derivative.exercise_date: The reporting person received restricted stock units under the Enochian BioSciences Inc. 2019 Equity Incentive Plan. 11,266 of the restricted stock units shall vest on the Grant Date; the remaining 5,000 restricted stock units shall vest on January 7, 2022. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. Read SEC document |
| December 16, 2021 Filed Jan 11, 2022 22:54 UTC Amendment | Lunai Bioworks Inc. ENOB · Entity 7981 | GrantCommon Stock | 16,266 | $0.00 | $0.00 |
DisclosureSEC source: 0001731122-22-000044 · ownership.xml · nonDerivative · entry 2 Puche Luisa · CIK 0001768468 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,266 F2 · shares: Ms. Puche received restricted stock units under the Issuer's 2019 Equity Incentive Plan. 11,266 of the restricted stock units vested on the Grant Date; the remaining 5,000 restricted stock units vested on January 7, 2022. Upon vesting, the reporting person received a number of shares of common stock equal to the number of restricted stock units that have vested. Read SEC document |
| December 16, 2021 Filed Jan 11, 2022 22:54 UTC Amendment | Lunai Bioworks Inc. ENOB · Entity 7981 | Disposition to issuerCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001731122-22-000044 · ownership.xml · nonDerivative · entry 1 Puche Luisa · CIK 0001768468 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: The Issuer cancelled the shares of common stock previously issued to Ms. Puche upon the vesting of certain restricted stock units. Read SEC document |
| October 26, 2021 Filed Nov 23, 2021 17:41 UTC | Lunai Bioworks Inc. ENOB · Entity 7981 | GrantOption to purchase shares of common stock · Derivative | 60,000 | $0.00 Strike: $8.58 | $0.00 |
DisclosureSEC source: 0001731122-21-002049 · ownership.xml · derivative · entry 1 Puche Luisa · CIK 0001768468 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common stock · 60,000 shares Expires 2031-10-26 F1 · derivative.exercise_date: The options vest ratably on October 26, 2022, October 26, 2023 and October 26, 2024. Read SEC document |
| January 07, 2020 Filed Jan 10, 2020 02:28 UTC | Lunai Bioworks Inc. ENOB · Entity 7981 | Exercise / conversionRestricted Stock Units · Derivative | 5,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001731122-20-000033 · ownership.xml · derivative · entry 2 Puche Luisa · CIK 0001768468 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 5,000 shares Expires 2029-01-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 07, 2020 Filed Jan 10, 2020 02:28 UTC | Lunai Bioworks Inc. ENOB · Entity 7981 | Exercise / conversionCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001731122-20-000033 · ownership.xml · nonDerivative · entry 1 Puche Luisa · CIK 0001768468 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 09, 2019 Filed Dec 21, 2021 00:01 UTC | Lunai Bioworks Inc. ENOB · Entity 7981 | OtherRestricted Stock Units · Derivative | 15,000 | $6.15 Strike: $6.15 | $92,250.00 |
DisclosureSEC source: 0001731122-21-002163 · ownership.xml · derivative · entry 2 Puche Luisa · CIK 0001768468 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2029-06-09 F3 · derivative.exercise_date: Reflects the decision of the Enochian BioSciences Inc. board of directors to void and rescind, nunc pro tunc, the grant of 15,000 RSUs previously approved on June 9, 2019, under the Issuer's 2019 Equity Incentive Plan. As of the date of this Form 4, 10,000 RSUs had vested; the reporting person has agreed to surrender the 10,000 shares of common stock underlying the RSUs to Enochian BioSciences Inc. for cancellation. Read SEC document |
| June 06, 2019 Filed Jun 21, 2019 20:36 UTC | Lunai Bioworks Inc. ENOB · Entity 7981 | GrantRestricted Stock Units · Derivative | 15,000 | $6.15 Strike: $6.15 | $92,250.00 |
DisclosureSEC source: 0001731122-19-000353 · ownership.xml · derivative · entry 2 Puche Luisa · CIK 0001768468 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2029-01-07 F2 · derivative.exercise_date: On June 6, 2019, Ms. Puche was granted fifteen thousand (15,000) restricted stock units, vesting in equal amounts annually over three years from January 7, 2019, the date of her appointment as Chief Financial Officer of Enochian Biosciences, Inc. Read SEC document |
| June 06, 2019 Filed Jun 21, 2019 20:36 UTC | Lunai Bioworks Inc. ENOB · Entity 7981 | GrantOption to Purchase Common Stock · Derivative | 60,000 | $6.15 Strike: $6.15 | $369,000.00 |
DisclosureSEC source: 0001731122-19-000353 · ownership.xml · derivative · entry 1 Puche Luisa · CIK 0001768468 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2029-01-07 F1 · derivative.exercise_date: On June 6, 2019, Ms. Puche was granted options to purchase sixty thousand (60,000) shares of the Company's common stock vesting in equal amounts annually over three years from January 7, 2019, the date of her appointment as Chief Financial Officer of Enochian Biosciences, Inc., pursuant to the Company's 2014 Equity Incentive Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.